Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
- Registration Number
- NCT01114581
- Lead Sponsor
- Reckitt Benckiser LLC
- Brief Summary
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
- Symptoms of cough, thickened mucus and chest congestion
- Able to produce sputum
- Non Smoker
Exclusion Criteria
- Pregnant
- Smokers
- Fever above 101°F
- Any chronic illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Guaifenesin Mucinex Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets Placebo Placebo Given as 2 tablets
- Primary Outcome Measures
Name Time Method Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs 3 hours following inhalation of radioactive tracer particles Percentage of inhaled radioactive tracer (Ave180Clear)
- Secondary Outcome Measures
Name Time Method Guaifenesin AUC(0-3) 3 hours following dose administration Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo. Within 10 days of developing symptoms associated with a respiratory tract infection
Trial Locations
- Locations (1)
Center for Environmental Medicine, Asthma, and Lung Biology
🇺🇸Chapel Hill, North Carolina, United States